Deerfield Management Company, L.P. (Series C) Catalyst Pharmaceuticals, Inc. Put Options Transaction History
Deerfield Management Company, L.P. (Series C)
- $5.38 Billion
- Q3 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding CPRX
# of Institutions
327Shares Held
94.6MCall Options Held
19.1KPut Options Held
51.1K-
Black Rock Inc. New York, NY18.7MShares$402 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.04MShares$173 Million0.0% of portfolio
-
State Street Corp Boston, MA5.69MShares$122 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.02MShares$64.8 Million0.01% of portfolio
-
Pacer Advisors, Inc. Malvern, PA2.8MShares$60.2 Million0.13% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.21B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...